Overview

RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC

Status:
Not yet recruiting
Trial end date:
2026-09-01
Target enrollment:
Participant gender:
Summary
an open, single-arm, multicenter phase Ib/II study
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
RemeGen Co., Ltd.